Effect of probiotic supplement on improvement of depressive symptoms in patients with substance-induced depressive disorder: a randomized, double-blind, placebo-controlled clinical trial.

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

Substance-Induced Depressive Disorder (SIDD) accounts for a high health burden and requires new therapies.

Bidirectional communications between the gut and the brain mediated by the microbiota point to a possible influence of probiotics as a tool for preserving mental health.

Who Took Part

The study group was 40 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Double-blind, placebo-controlled, randomized clinical trial on a sample of 40 patients with SIDD.

Patients were then randomly assigned into probiotic and placebo arms and underwent interventions for four continuous weeks.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Copper (Supplement).

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

The clinical assessment was done using BDI and HAM-A.

Immunologic outcomes were measured through analysis of inflammatory markers, cytokines, and other immunological parameters.

The trial was registered with ClinicalTrials.gov, under the identifier NCT06790823 (18/1/2025).

What Was Measured

Topics PubMed links to this paper include Probiotics, Depression, Depressive Disorder, Pilot Projects, Cytokines and Anxiety.

The authors tagged it with the keywords Clinical trial, Opium and Substance.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 40 patients.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (BMC psychiatry), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.